AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic Regulation

Executive Summary: AZ505 is a small-molecule SMYD2 inhibitor with high potency (IC₅₀ = 0.12 μM) and selectivity over other methyltransferases, including SMYD3, DOT1L, and EZH2 (IC₅₀ > 83.3 μM) (DOI). It acts as a substrate-competitive inhibitor, binding the peptide substrate groove of SMYD2 without competing with the co-factor S-adenosylmethionine. AZ505 is soluble in DMSO and stable at -20°C (APExBIO). It is validated for research in epigenetic regulation, cancer biology, and fibrotic disease models where SMYD2 is implicated. The compound is not for diagnostic or therapeutic use.

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a protein lysine methyltransferase. It methylates histone substrates H2B, H3 (notably H3K36), and H4, as well as non-histone proteins such as p53 and retinoblastoma protein (Rb) (Chen et al. 2023). SMYD2-mediated methylation alters chromatin architecture and gene transcription, impacting processes like cell cycle control, DNA repair, and oncogenesis. Overexpression of SMYD2 is documented in various cancers, including gastric cancer and esophageal squamous cell carcinoma (ESCC), and is linked to poor prognosis (APExBIO). Epigenetic regulation via histone methylation is also implicated in fibrosis and chronic kidney disease (CKD), with SMYD2 acting as a critical modulator in these pathological contexts.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 functions as a substrate-competitive inhibitor of SMYD2. It binds to the peptide substrate binding groove of the enzyme, preventing methylation of lysine residues on both histone and non-histone proteins. Notably, AZ505 does not compete with the methyl donor co-factor S-adenosylmethionine (SAM), which distinguishes it from many enzyme inhibitors (Chen et al. 2023). AZ505 displays strong inhibitory activity with an IC₅₀ of 0.12 μM and a K_i of 0.3 μM under standard assay conditions (37°C, buffered aqueous solutions) (APExBIO). The compound’s selectivity has been confirmed against SMYD3, DOT1L, and EZH2, where the IC₅₀ values exceed 83.3 μM, indicating minimal off-target effects on other histone methyltransferases.

Evidence & Benchmarks

• AZ505 inhibits SMYD2-mediated methylation of histone H3K36 in vitro and in cell-based assays (Chen et al. 2023, DOI).
• In cisplatin-induced chronic kidney disease (CKD) models, AZ505 administration reduces SMYD2 expression, renal fibrosis, and inflammatory cytokines such as IL-6 and TNF-α (Chen et al. 2023, DOI).
• AZ505 specifically blocks the epithelial-mesenchymal transition (EMT) and downregulates fibrosis-related proteins in tubular epithelial cells (Chen et al. 2023, DOI).
• AZ505 exhibits high selectivity for SMYD2 over other methyltransferases (IC₅₀ > 83.3 μM for SMYD3, DOT1L, EZH2) (APExBIO).
• AZ505 is soluble in DMSO and stable at -20°C, with improved solubility upon warming to 37°C and ultrasonic shaking (APExBIO).

This article extends mechanistic perspectives found in AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic Applications by providing updated evidence from CKD models and detailed workflow integration. For a translational overview, see AZ505 and the Future of SMYD2 Inhibition, which discusses broader clinical implications. For a focused analysis on fibrosis modeling, compare with AZ505: Advancing SMYD2 Inhibition for Epigenetic and Fibrotic Research.

Applications, Limits & Misconceptions

AZ505 is widely used in:

• Epigenetic regulation research: Dissecting histone methylation and gene expression control.
• Cancer biology research: Investigating SMYD2’s role in tumorigenesis, especially in gastric cancer and ESCC where SMYD2 is overexpressed (APExBIO).
• Fibrosis and CKD models: Blocking SMYD2 activity to study pathways of renal fibrosis (Chen et al. 2023).
• Protein lysine methyltransferase inhibition studies: Benchmarking selectivity and potency versus other inhibitors.

Common Pitfalls or Misconceptions

• AZ505 is not a pan-methyltransferase inhibitor; it does not inhibit SMYD3, DOT1L, or EZH2 at relevant concentrations.
• Not suitable for in vivo therapeutic use—intended for research only.
• Solubility is limited in aqueous buffers; DMSO and warming (37°C) with ultrasonic agitation are required for optimal dissolution.
• AZ505 does not reverse established fibrosis but prevents progression in preclinical models.
• Not validated for diagnostic applications or clinical monitoring.

Workflow Integration & Parameters

Preparation: Dissolve AZ505 in DMSO to prepare a concentrated stock solution (e.g., 10 mM). Warming at 37°C and brief ultrasonic shaking enhance solubility.

Storage: Store aliquoted solutions at -20°C. Avoid repeated freeze-thaw cycles.

Assay Conditions: For in vitro SMYD2 inhibition, recommended working concentrations range from 0.1 μM to 1 μM. Use buffered aqueous solutions and maintain pH 7.4. For cell-based assays, dilute DMSO stocks into culture media (final DMSO < 0.1%).

Controls: Include negative controls (vehicle/DMSO) and positive controls (active SMYD2 substrates) in all experimental workflows.

Refer to AZ505, a potent and selective SMYD2 inhibitor (SKU B1255, APExBIO) for detailed protocols and additional product data.

Conclusion & Outlook

AZ505 represents a benchmark tool for dissecting SMYD2-dependent epigenetic mechanisms. Its high potency, substrate-competitive inhibition, and selectivity profile enable robust modeling of histone methylation pathways and disease processes including cancer and fibrosis. Ongoing research continues to refine its utility in translational models. Caution is warranted regarding its research-only status and solubility parameters. For deeper mechanistic and translational context, APExBIO provides up-to-date documentation and peer-reviewed references on the B1255 product page.